Mode
Text Size
Log in / Sign up
N/A N=3 Treatment

SCED - Wisdom Enhancement for Post-Stroke Depression

Post-stroke Depression

Enrolled (actual)
3
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Visual Analogue Scale (VAS) - Mood — 3.53; 5.23 Scores on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Timeline Intervention (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of East Anglia
Primary completion
Feb 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analogue Scale (VAS) - Mood
3.53; 5.23
PRIMARY
Visual Analogue Scale (VAS) - Identity
2.55; 5.09
PRIMARY
Visual Analogue Scale (VAS) - Wisdom
2.79; 5.56
PRIMARY
Visual Analogue Scale (VAS) - Self-esteem
3; 4.92
SECONDARY
Patient Health Questionnaire (PHQ-9)
13.66; 7.33

Summary

One-third of stroke survivors experience post-stroke depression, but there are currently no official guidelines for supporting them. Researchers aim to investigate whether the wisdom enhancement timeline technique can reduce depression in stroke survivors. The investigators also want to understand how this technique positively impacts mood, identity, self-esteem, and wisdom. The study will involve nine stroke survivors from the National Health Service (NHS) to gain insights into effective ways to support those with post-stroke depression.

Eligibility Criteria

Inclusion Criteria

  • Had a stroke.
  • Those who self-report as having difficulties with depression to a clinician.
  • Have sufficient cognitive and communication abilities for informed consent and active engagement

Exclusion Criteria

  • Under the age of 18. Because this is the age when they are treated as an adult by UK law.
  • Severe cognitive impairments or mental health difficulties that would hinder task engagement or provide informed consent.
  • Medical instability jeopardising consistent participation or well-being.
  • Significant risk concerns regarding safety to themselves or others.
  • Substance use/dependency impacting adherence.
  • Prescribed psychotropic medication less than 3 months ago.
  • Currently involved in research.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06451965). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search